Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus VERSAPEN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus VERSAPEN K.
PENICILLIN G POTASSIUM vs VERSAPEN-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
VERSAPEN-K (hetacillin potassium) is a prodrug that is hydrolyzed to ampicillin, which inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
250-500 mg intramuscularly or intravenously every 6 hours for moderate infections; 1-2 g every 6 hours for severe infections.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
0.8-1.5 hours in adults with normal renal function (prolonged to 6-20 hours in severe renal impairment; dosing adjustment required when CrCl <30 mL/min).
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: 15-20% as active drug; fecal: <5%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic